Abstract
Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient disruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, intrinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional chemotherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miRNAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anticancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we present an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberrations in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets.
Keywords: Chemotherapy, lung cancer, microRNA, oncogenic pathways, resistance, targeted agents.
Current Pharmaceutical Biotechnology
Title:Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Volume: 15 Issue: 5
Author(s): Christian Rolfo, Daniele Fanale, David S. Hong, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Patrick Pauwels, Jan P. Van Meerbeeck, Stefano Caruso, Viviana Bazan, Giuseppe Cicero, Antonio Russo and Elisa Giovannetti
Affiliation:
Keywords: Chemotherapy, lung cancer, microRNA, oncogenic pathways, resistance, targeted agents.
Abstract: Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient disruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, intrinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional chemotherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miRNAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anticancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we present an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberrations in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets.
Export Options
About this article
Cite this article as:
Rolfo Christian, Fanale Daniele, Hong S. David, Tsimberidou M. Apostolia, Piha-Paul A. Sarina, Pauwels Patrick, Meerbeeck P. Van Jan, Caruso Stefano, Bazan Viviana, Cicero Giuseppe, Russo Antonio and Giovannetti Elisa, Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519123219
DOI https://dx.doi.org/10.2174/1389201015666140519123219 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Strategies for Rectal Cancer Initial Staging: Does Pelvic Computed Tomography Provide Significantly Additional Findings when High-resolution Magnetic Resonance Imaging has Been Performed?
Current Medical Imaging Advances in the Application of Liposomal Nanosystems in Anticancer Therapy
Current Stem Cell Research & Therapy XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Current Molecular Medicine Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Drug Delivery Systems for Photodynamic Therapy
Recent Patents on Drug Delivery & Formulation Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Real-life Field Studies of the NOx Removing Properties of Photocatalytic Surfaces in Roskilde and Copenhagen Airport, Denmark
Journal of Photocatalysis Policies to Prevent Tobacco Use and Exposure in Children, a Global Perspective
Current Pediatric Reviews Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Na, K-ATPase as a Biological Target for Gold(III) Complexes: A Theoretical and Experimental Approach
Current Medicinal Chemistry Current Challenges and Implications of Proteogenomic Approaches in Prostate Cancer
Current Topics in Medicinal Chemistry